Prof. Dr. Gökşen İnanç İmamoğlu
Is this your profile? Claim it and verify your details.
Claim profilePerson ↔ Disease
Which diseases does this doctor work on?
-
Breast Neoplasms 10 publicationsSource: OpenAlex / PubMed MeSHView publications
- Prostatic Neoplasms 2 publications
- Colorectal Neoplasms 2 publications
- Head and Neck Neoplasms 2 publications
- Stomach Neoplasms 2 publications
- Lung Neoplasms 2 publications
- Neoplasms 2 publications
- COVID-19 2 publications
- Carcinoma, Renal Cell 2 publications
- Kidney Neoplasms 2 publications
Trust
Where does this information come from?
The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.
- Department name at the sourceOnkolojisaglik.gov.trFrom source
- InstitutionAnkara Etlik Şehir Hastanesisaglik.gov.trFrom source
- Area of workBreast NeoplasmsExtracted from 10 publications · Model version —From source
- Publications77 publicationsOpenAlex, Europe PMCFrom source
- ORCID0000-0003-0356-0727ORCIDFrom source
- Last synchronised5 November 2026 07:23https://etliksehir.saglik.gov.tr/TR-864408/klinik-doktorlarimiz.html#goksen-inanc-imamoglusaglik.gov.tr
Scientific work
Publications on Breast Neoplasms
-
Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study
Current Oncology, 2026
DOI 10.3390/curroncol33060365 PMID 42346265 Open-access full textSource: OpenAlex
-
Quantifying the Survival Benefit of Trimodality Therapy in Esophageal Squamous Cell Carcinoma: An IPTW-adjusted Retrospective Analysis
Acta haematologica oncologica Turcica., 2026
DOI 10.4274/ahot.galenos.2026.2026-4-6 Open-access full textSource: OpenAlex
-
Association Between Treatment-Emergent Pancreatic Volume Loss and Survival Outcomes in Patients with Metastatic Colorectal Cancer Receiving Bevacizumab
Medicina, 2026
DOI 10.3390/medicina62081459 PMID 42654356 Open-access full textSource: OpenAlex
-
Baseline 25-hydroxyvitamin D and progression-free survival in de novo metastatic hormone-sensitive prostate cancer: prognostic model development and external validation
The oncologist, 2026
DOI 10.1093/oncolo/oyag396 PMID 42836684 Open-access full textSource: Europe PMC
-
Impact of Prior mRNA COVID-19 Vaccination on PFS2 in NSCLC Patients Receiving Second-Line Immune Checkpoint Inhibitors: A Real-World Analysis
Journal of Clinical Medicine, 2026
DOI 10.3390/jcm15072475 PMID 41976774 2 citations (OpenAlex) Open-access full textSource: OpenAlex
-
Prognostic Role of Nutritional and Inflammatory Indices in Predicting Adverse Clinical Outcomes in Unplanned Hospitalized Oncology Patients
Journal of Clinical Medicine, 2026
DOI 10.3390/jcm15082992 PMID 42074794 2 citations (OpenAlex) Open-access full textSource: OpenAlex
-
Structural Acceleration in Sepsis-Associated Cancer Mortality in an Aging Population: A Nationwide Study in the United States, 1999–2020
SSRN Electronic Journal, 2026
DOI 10.2139/ssrn.6201853 Open-access full textSource: OpenAlex
-
The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study
Scientific Reports, 2026
DOI 10.1038/s41598-026-44980-w PMID 41888201 Open-access full textSource: OpenAlex
-
Temporal trends in venous thromboembolism–related mortality among gastric cancer deaths in the United States, 1999–2020.
Turkish Journal of Clinics and Laboratory, 2026
DOI 10.18663/tjcl.1893840 Open-access full textSource: OpenAlex
-
The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor–positive, HER-2–negative metastatic breast cancer: A real-world, multicenter, retrospective study.
Journal of Clinical Oncology, 2026
DOI 10.1200/jco.2026.44.16_suppl.e24144 Source: OpenAlex